Navigation Links
uBiome Appoints Dr. Jonathan Braun, MD, PhD, Prominent UCLA Physician-Researcher, to its Scientific Advisory Board
Date:10/26/2018

uBiome, the leader in microbial genomics, announces the addition of Dr. Jonathan Braun, MD, PhD, Chair of the Department of Pathology and Laboratory Medicine at University of California Los Angeles (UCLA), to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Braun will bring to uBiome a deep expertise on the role of the immune system in resistance and susceptibility to inflammatory bowel disease and cancer. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Braun is a respected clinician, researcher, and professor with extensive knowledge about the pathology of IBD and other critical conditions,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are extremely fortunate to have him as new addition to uBiome’s Scientific Advisory Board.”

Dr. Braun serves as a Professor of Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA and as the chair of the Department of Pathology and Laboratory Medicine. Previously, Dr. Braun served as the chairman of the National Scientific Advisory Board of the Crohn's and Colitis Foundation, president of both the Clinical Immunology Society and the Federation of Clinical Immunology Societies (FOCIS), and on the editorial boards of Gastroenterology, Inflammatory Bowel Diseases, and Clinical Immunology. He has published more than 75 primary research studies, 14 issued patents, and co-founded three biopharma companies.

About joining uBiome's Scientific Advisory Board, Dr. Braun said, “As a GI investigator, I am keenly aware of the diverse impact of the microbiomes of the body on health. As a pathologist, I am motivated by the need to develop robust and accessible strategies to monitor the microbiome across time, personal activities, and intentional interventions. uBiome is a leader in developing and disseminating such strategies and thereby advancing both the science and its adoption by the broader community.”

In addition to Dr. Braun, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Read the full story at https://www.prweb.com/releases/ubiome_appoints_dr_jonathan_braun_md_phd_prominent_ucla_physician_researcher_to_its_scientific_advisory_board/prweb15863468.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Appoints Kathie Swift, MS, RDN, FAND, Co-founder of the Integrative and Functional Nutrition Academy, to its Scientific Advisory Board
2. uBiome Appoints Dr. Steven Medwell, MD, Distinguished Colorectal Surgeon, to its Medical Advisory Board
3. Veridium Appoints Former HSBC Fintech Head James Stickland as New CEO
4. BioCatch Appoints Eyal Goldwerger as CEO
5. Genisphere Appoints New CEO, Thomas Bliss
6. Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer
7. MedNet Appoints Clareece West As Chief Operating Officer
8. Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
9. EyeLock Appoints Roger An Vice President of Global Market Development
10. EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts
11. EyeLock Appoints Darlene Crumbaugh Vice President of Financial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... ... January 03, 2019 , ... Over the last ... their drug discovery research workflows with biology ranging from single cell-type spheroids to ... in vitro studies, they create several challenges that need to be overcome in ...
(Date:12/25/2018)... , ... December 24, 2018 , ... ... The Rockefeller University have discovered a new use for a long-standing computational concept ... spam control, blocking unwanted files and messages. Using blacklisting as a filter to ...
(Date:12/19/2018)... ... , ... InTouchMD’s flagship product, Pulse , has been honored by PM360 ... is featuring the recognition in its 7th annual Innovations issue, created for purpose of ... medical device industries. , “This recognition comes at an exciting time for Pulse as ...
Breaking Biology News(10 mins):
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. ... Disease drug candidate, code-named "KM-819." KM-819 is an orally active small molecule ... in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study ...
(Date:12/20/2018)... ... , ... New Year’s brings reflection and desire to improve for individuals and ... (EU) on the horizon, Jim Kasic, president and CEO of Boulder iQ, suggests five ... Device Regulation (MDR), digital health, and big data are just a few of the ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial ... (human) ingredient. This has been part of their strategic plan and an important ... certification creates custom fermentation opportunities for MDG within the $44 Billion human probiotic ...
Breaking Biology Technology: